Buscar

Estamos realizando la búsqueda. Por favor, espere...

Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-? antagonist therapy

Abstract: Objectives: Osteoprotegerin (OPG) has been associated with increased risk and severity of atherosclerotic disease in the general population. Since ankylosing spondylitis (AS) is a chronic inflammatory disease associated with accelerated atherosclerosis, we aimed to assess whether OPG levels correlate with disease activity, systemic inflammation, metabolic syndrome, adipokines and biomarkers of endothelial cell activation in patients with AS undergoing TNF-? antagonist therapy. Methods: We assessed OPG plasma concentration in 30 non-diabetic AS patients without cardiovascular disease undergoing TNF-? antagonist-infliximab therapy. OPG levels were measured immediately before and after an infliximab infusion. Correlations of OPG levels with disease activity, clinical characteristics, systemic inflammation, metabolic syndrome features, adipokines and biomarkers of endothelial activation were assessed. Changes in OPG concentration following an infusion of anti-TNF-? monoclonal antibody-infliximab were also analysed. Results: We found a positive correlation between OPG levels and markers of disease activity such as BASDAI and VAS spinal pain (r=0.497, p=0.01; r=0.390; p=0.04, respectively). No differences in OPG levels according to specific clinical features of the disease were seen. An inverse correlation between OPG levels and total cholesterol and LDL-cholesterol was also found (r=-0.451; p=0.02 and r=-0.411; p=0.03, respectively). A correlation between OPG and asymmetric dimethylarginine, a biomarker of endothelial cell activation, was also disclosed (r=0.533; p=0.01). No correlation between OPG level and insulin resistance was observed. An infliximab infusion did not lead to a significant reduction in OPG levels. Conclusions: OPG shows a correlation with markers of disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-? antagonist therapy.

 Fuente: Clinical and Experimental Rheumatology, 2014, 32(5), 640-646

 Editorial: Clinical and Experimental Rheumatology

 Año de publicación: 2014

 Nº de páginas: 7

 Tipo de publicación: Artículo de Revista

 ISSN: 0392-856X,1593-098X

Autoría

GENRE, FERNANDA

LÓPEZ-MEJÍAS, RAQUEL

MIRANDA-FILLOY, JOSÉ A.

UBILLA, BEGOÑA

CARNERO-LÓPEZ, BEATRIZ

PALMOU-FONTANA, NATALIA

BLANCO, RICARDO

RUEDA-GOTOR, JAVIER

PINA, TRINITARIO

GONZÁLEZ-JUANATEY, CARLOS

FRANCISCO JAVIER LLORCA DIAZ

GONZÁLEZ-GAY, MIGUEL Á.